⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MYGN News
Myriad Genetics Inc
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
globenewswire.com
MYGN
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
globenewswire.com
MYGN
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
globenewswire.com
MYGN
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026
globenewswire.com
MYGN
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
globenewswire.com
MYGN
Myriad Genetics, Inc. Investigated by the Portnoy Law Firm
globenewswire.com
MYGN
Liquid Biopsy Products Market Report 2026-2031 Featuring Analysis of Roche, Illumina, Qiagen, MDxHealth, Novogen, BGI, Myriad Genetics and More
globenewswire.com
ILMN
QGEN
MDXH
MYGN
ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests
businesswire.com
REGN
AMGN
ABT
TMO
RVTY
MYGN
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
globenewswire.com
MYGN
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer
prnewswire.com
TLX
MYGN